Consider Hims & Hers Health (HIMS) as a key investment opportunity, as its stock price appears disconnected from its recent launch of a low-cost, oral GLP-1 weight loss drug. The company is offering its compounded oral semaglutide at just $49 per month, directly challenging expensive brand-name competitors. This disruptive pricing poses a significant threat to legacy pharmaceutical companies like Novo Nordisk (NVO), which is viewed as a stock to avoid due to competitive and legal pressures. For long-term exposure to the GLP-1 theme, Eli Lilly (LLY) is positioned as a strong innovator with its next-generation drug, Retatrutide, expected around the end of 2026. The core strategy involves investing in the disruption of the high-priced drug market through companies like HIMS and long-term innovators like LLY.

Hims & Hers Health, Inc. (HIMS)

• Major Announcement: HIMS has launched a compounded oral semaglutide (a GLP-1 weight loss drug) at a price point of $49 per month for the first six months.
  • This is positioned as being 10 times cheaper than the branded, non-compounded versions.
  • The oral pill format is a significant development, as it targets a large portion of the population (one in five people) who have a phobia of needles, potentially expanding the market for GLP-1s.
• Market Reaction: Despite what the speaker calls "amazing news," the stock was down over 2% at the time of recording. The speaker believes the stock price is completely disconnected from the company's strong fundamental execution and is being treated as a "punching bag" by Wall Street.
• Business Strategy:
  • HIMS is focused on providing affordable healthcare and positioning itself as "the company of the people."
  • The company is innovating beyond just GLP-1s, having recently launched at-home lab services and a cancer test for $6.99 that screens for over 50 types of cancer.
  • The speaker believes the future of medicine is personalization and compounding, where drugs are customized for each individual. HIMS is seen as a leader in this "one-to-one medicine" trend.
• Legal Risks & Defense:
  • Novo Nordisk is threatening legal action, but HIMS's defense appears strong.
  • Compounding is a legally permitted practice in the United States under the FDA.
  • HIMS claims to have developed its own proprietary delivery method for the oral pill and is not using Novo's patented SNAC technology.
• Future Opportunities:
  • If compounding semaglutide were to be disallowed, HIMS could potentially pivot to compounding Liraglutide, a similar drug that is now off-patent. A daily oral pill of Liraglutide could also be a blockbuster product.
  • The speaker speculates HIMS may eventually compound next-generation drugs from Eli Lilly, such as Tirzepatide and Retatrutide.

Takeaways

• The speaker is extremely bullish on HIMS's long-term business strategy, management execution, and disruptive position in the massive GLP-1 market.
• The current negative stock price action is seen as a "joke" and a potential opportunity for long-term investors, as it does not reflect the positive fundamental developments.
• The legal threats from Novo Nordisk are viewed as a low-to-medium risk, given that compounding is legal in the U.S. and any legal battle could take 4 to 8 years, by which time the market may have moved on to newer drugs.
• HIMS appears to have a backup plan (compounding off-patent Liraglutide) which provides an additional layer of safety for its business model.

Novo Nordisk (NVO)

• Competitive Threat: Novo Nordisk, a major producer of branded GLP-1s, is facing direct competition from HIMS's low-cost compounded oral semaglutide.
• Market Reaction: Novo's stock was down nearly 7% following the HIMS announcement.
• Company Actions:
  • Novo is threatening to sue HIMS, calling their product an "untested semaglutide knockoff."
  • The speaker is highly critical of Novo, calling the company "dysfunctional."
  • Criticisms include the legal threat being issued from Denmark in "British English" (showing a disconnect from the US market) and a past failure to renew semaglutide patents in Canada.
• Legal Position: The speaker believes Novo's legal case is weak because compounding is allowed by the FDA and previous suits against other compounders have been dismissed.

Takeaways

• The speaker's sentiment towards Novo Nordisk is bearish.
• Novo is portrayed as a slow-moving legacy pharmaceutical company being outmaneuvered by a more agile and innovative competitor.
• The threat of legal action is seen more as a sign of weakness than strength, and it is unlikely to stop HIMS in the short-to-medium term. Investors should monitor for headwinds from increased competition and potential loss of market share to lower-cost alternatives.

Eli Lilly and Company (LLY)

• Market Position: Mentioned as another dominant player in the GLP-1 market and a key competitor to Novo Nordisk.
• Political Favor: The speaker suggests the U.S. government and certain states (like Indiana) are "pro-Lilly" and may even take action to protect Lilly's market from compounders.
• Future Pipeline: Lilly's next-generation drug, Retatrutide, is described as the potential "end of the game" for the current class of GLP-1s. It is expected to be approved around the end of 2026.

Takeaways

• Eli Lilly is positioned as a strong, long-term leader in the weight-loss drug market.
• Its upcoming drug, Retatrutide, is a significant future catalyst that could reshape the entire industry.
• The company appears to have strong political support in the U.S., which could provide a competitive advantage.

Investment Theme: GLP-1s and Compounding Pharmacies

• Market Size: The GLP-1 market is described as the "miracle drug of our century" and a massive blockbuster category. The CEO of Eli Lilly is cited as predicting that one in three Americans could be on a GLP-1 drug by 2030.
• Disruption: The traditional pharmaceutical model of patenting a modified natural compound and charging high prices is being disrupted by compounding pharmacies.
• Political Climate: The current U.S. administration is focused on lowering drug costs, which creates a favorable environment for lower-cost providers like HIMS and a challenging one for high-priced brands like Novo Nordisk. The speaker cites UnitedHealthcare (UNH) dropping on news it couldn't raise prices as an example of this trend.
• The Future of Medicine: The discussion highlights a major shift towards personalized medicine, where drugs are compounded and customized for the individual patient, rather than a one-size-fits-all approach.

Takeaways

• The GLP-1 space represents a massive, long-term growth opportunity for investors.
• There are two main ways to invest in this theme:
  • Disruptors: Companies like HIMS that use compounding to offer low-cost, convenient access to these drugs.
  • Innovators: Companies like Eli Lilly that are developing the next generation of even more effective drugs.
• The traditional business model of companies like Novo Nordisk is under significant threat from both competition and political pressure to lower prices.